Advertisement

Cost-Effectiveness of ICD Implantation in Clinical Settings Different From Ischemic Heart Disease: What Do We Know?

  • G. Boriani
  • M. Biffi
  • C. Martignani
  • C. Greco
  • C. Camanini
  • C. Valzania
  • I. Diemberger
  • F. Cecaro
  • A. Branzi
Conference paper

Abstract

Sudden cardiac death is responsible for around 50% of all deaths due to cardiovascular causes [1, 2]. The implantable cardioverter defibrillator (ICD) was initially conceived by Mirowski for preventing sudden death in patients who have already experienced a life-threatening ventricular arrhythmia, such as sustained ventricular tachycardia or ventricular fibrillation. These patients are at high risk of recurrences of these malignant tachyarrhythmias, with recurrence rates around 30%–50% in a 2-year follow-up period [3]. Prospective controlled studies have demonstrated that ICDs prevent sudden death in these patients, with an improvement in overall survival in a 3- to 5-year follow- up[4–6]. The majority of patients enrolled in these trials had coronary artery disease as predominant etiology, and a wide range of ventricular function compromise was present, as well as a wide range of associated clinical conditions

Keywords

Sudden Death Sudden Cardiac Death Implantable Cardioverter Defibrillator Hypertrophic Cardiomyopathy Idiopathic Dilate Cardiomyopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zipes DP, Wellens HJ ( 1998) Sudden cardiac death. Circulation 98:2334–2351PubMedCrossRefGoogle Scholar
  2. 2.
    Priori SG, Aliot E, Blomstrom-Lundqvist C et al (2001) Task Force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 16:1374–1450CrossRefGoogle Scholar
  3. 3.
    Gregoratos G, Abrams J, Epstein AE et al (2002) ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/NASPE committee to update the 1998 pacemaker guidelines). J Am Coll Cardiol 40:1703–1719PubMedCrossRefGoogle Scholar
  4. 4.
    The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators (1997) A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337:1576–1583CrossRefGoogle Scholar
  5. 5.
    Connolly SJ, Gent M, Roberts RS et al (2000) Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amio-darone. Circulation 101:1297–1302PubMedCrossRefGoogle Scholar
  6. 6.
    Ezekowitz JA, Armstrong PW, McAlister FA (2003) Implantable cardioverter defibrillators in primary and secondary prevention:a systematic review of randomized, controlled trials. Ann Intern Med 138:445–452PubMedGoogle Scholar
  7. 7.
    Moss AJ (2000) Implantable cardioverter defibrillator therapy: the sickest patients benefit the most. Circulation 101:1638–1640PubMedCrossRefGoogle Scholar
  8. 8.
    Kupersmith J, Holmes-Rovner M, Rovner D et al (1995) Cost-effectiveness analysis in heart disease. Part II. Preventive therapies. Prog Cardiovasc Dis 37:243–271PubMedCrossRefGoogle Scholar
  9. 9.
    Kupersmith J, Holmes-Rovner M, Rovner D et al (1995) Cost-effectiveness analysis in heart disease. Part III. Ischemia, congestive heart failure and arrhythmias. Prog Cardiovasc Dis 37:307–346PubMedCrossRefGoogle Scholar
  10. 10.
    Kuppermann M, Luce BR, McGovern B et al (1990) An analysis of the cost effectiveness of the implantable defibrillator. Circulation 81:91–100PubMedCrossRefGoogle Scholar
  11. 11.
    Boriani G, Biffi M, Martignani C et al (2001) Cost-effectiveness of implantable cardioverterdefibrillators. Eur Heart J 22:990–996PubMedCrossRefGoogle Scholar
  12. 12.
    Hlatky MA, Bigger JT (2001) Cost-effectiveness of the implantable cardioverter defi-brillator? Lancet 357:1817–1818PubMedCrossRefGoogle Scholar
  13. 13.
    Fuster V, Gersh BJ, Giuliani ER et al (1981) The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 47:525–531PubMedCrossRefGoogle Scholar
  14. 14.
    Follansbee WP, Michelson EL, Morganroth J (1980) Nonsustained ventricular tachycardia in ambulatory patients: characteristics and association with sudden cardiac death. Ann Intern Med 92:741–747PubMedGoogle Scholar
  15. 15.
    Bansch D, Antz M, Boczor S et al (2002) Primary prevention of sudden cardiac death in idiopathic dilated dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 105:1453–1458PubMedCrossRefGoogle Scholar
  16. 16.
    Weintraub WS, Cole J, Tooley JF (2002) Cost and cost-effectiveness studies in heart failure research. Am Heart J 143:565–576PubMedCrossRefGoogle Scholar
  17. 17.
    Spirito P, Bellone P, Harris KM et al (2000) Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342:1778–1785PubMedCrossRefGoogle Scholar
  18. 18.
    Maron BJ (2002) Hypertrophic cardiomyopathy:a systematic review. JAMA 287:1308–1320PubMedCrossRefGoogle Scholar
  19. 19.
    Maron BJ, Shen WK, Link MS et al (2000) Efficacy of implantable cardioverter-defi-brillators for the prevention of sudden death in patients with hypertrophie cardiomyopathy. N Engl J Med 10; 365–373CrossRefGoogle Scholar
  20. 20.
    Corrado D, Basso C, Nava A et al (2001) Arrhythmogenic right ventricular cardiomyopathy: current diagnostic and management strategies. Cardiol Rev 9:259–265PubMedCrossRefGoogle Scholar
  21. 21.
    Boriani G, Gallina M, Merlini L et al (2003) Clinical relevance of atrial fibrillation/flutter, stroke, pacemaker implant, and heart failure in Emery-Dreifuss muscular dystrophy: a long-term longitudinal study. Stroke 34:901–908PubMedCrossRefGoogle Scholar
  22. 22.
    Becane HM, Bonne G, Varnous S et al (2000) High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin Electrophysiol 11:1661–1666CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2004

Authors and Affiliations

  • G. Boriani
    • 1
  • M. Biffi
    • 1
  • C. Martignani
    • 1
  • C. Greco
    • 1
  • C. Camanini
    • 1
  • C. Valzania
    • 1
  • I. Diemberger
    • 1
  • F. Cecaro
    • 1
  • A. Branzi
    • 1
  1. 1.Institute of CardiologyUniversity of BolognaItaly

Personalised recommendations